

Dermatology	Severe Plaque Psoriasis	Ustekinumab	Initiation	Ustekinumab Third Line: Severe Plaque Psoriasis TA 180 ADULT PATIENTS - Initiation Form (Local preferred options are etanercept, secukinumab, or ada	16 weeks	Tick box
Dermatology	Atopic Dermatitis	Dupilumab	Continuation	Dupilumab: Atopic Dermatitis TA 534 ADULT PATIENTS - Continuation Form	12 months	Tick box
Dermatology	Atopic Dermatitis	Dupilumab	Initiation	Dupilumab: Atopic Dermatitis TA 534 ADULT PATIENTS - Initiation Form	16 weeks	Tick box
Dermatology	Severe Chronic Hand Eczema	Alitretinoin	Initiation	Alitretinoin: Severe Chronic Hand Eczema TA 177 ADULT PATIENTS - Initiation Form	12 weeks	Tick box
Dermatology	Severe Chronic Hand Eczema	Alitretinoin	Repeat course	Alitretinoin: Severe Chronic Hand Eczema TA 177 ADULT PATIENTS - Repeat Course following Relapse	12 weeks	Tick box
Dermatology	Chronic Spontaneous Urticaria	Omalizumab	Initiation	Omalizumab: Chronic Spontaneous Urticaria TA 339 ADULT PATIENTS - Initiation Form	24 weeks	Tick box
Dermatology	Chronic Spontaneous Urticaria	Omalizumab	Repeat course	Omalizumab: Chronic Spontaneous Urticaria TA 339 ADULT PATIENTS - Repeat Course following Relapse	24 weeks	Tick box
Gastroenterology						
Gastroenterology	Chrons Disease	Adalimumab	Continuation	Adalimumab and Infliximab: Crohns disease TA 187 ADULT PATIENTS - Continuation Form	12 months	Tick box
Gastroenterology	Chrons Disease	Adalimumab	Initiation	Adalimumab and Infliximab: Crohns disease TA 187 ADULT PATIENTS - Initiation Form	12 weeks	Tick box
Gastroenterology	Chrons Disease	Adalimumab	Dose escalation	Adalimumab: Crohns disease TA 187 ADULT PATIENTS - Dose Escalation Notification	12 weeks	Tick box
Gastroenterology	Chrons Disease	Adalimumab	Ongoing dose escalation	Adalimumab: Crohns disease TA 187 ADULT PATIENTS - Ongoing Dose Escalation Prior Approval Form	12 weeks	Prior approval
Gastroenterology	Chrons Disease	Infliximab	Continuation	Adalimumab and Infliximab: Crohns disease TA 187 ADULT PATIENTS - Continuation Form	12 months	Tick box
Gastroenterology	Chrons Disease	Infliximab	Initiation	Adalimumab and Infliximab: Crohns disease TA 187 ADULT PATIENTS - Initiation Form	12 weeks	Tick box
Gastroenterology	Chrons Disease	Infliximab	Dose escalation	Infliximab: Crohns disease TA 187 ADULT PATIENTS - Dose Escalation Notification	24 weeks	Tick box
Gastroenterology	Chrons Disease	Infliximab	Ongoing dose escalation	Infliximab: Crohns disease TA 187 ADULT PATIENTS - Ongoing Dose Escalation Prior Approval Form	24 weeks	Prior approval
Gastroenterology	Chrons Disease	Ustekinumab	Continuation	Ustekinumab: Crohns disease TA 456 ADULT PATIENTS - Continuation Form	12 months	Tick box
Gastroenterology	Chrons Disease	Ustekinumab	Initiation	Ustekinumab: Crohns disease TA 456 ADULT PATIENTS - Initiation Form	16 weeks	Tick box
Gastroenterology	Chrons Disease	Vedolizumab	Continuation	Vedolizumab: Crohns disease TA 352 ADULT PATIENTS - Continuation Form	12 months	Tick box
Gastroenterology	Chrons Disease	Vedolizumab	Initiation	Vedolizumab: Crohns disease TA 352 ADULT PATIENTS - Initiation Form	16 weeks	Tick box
Gastroenterology	Chrons Disease	Vedolizumab	Week 10 dose	Vedolizumab: Crohns disease TA 352 ADULT PATIENTS - Week 10 dose Notification Form	1 dose	Tick box
Gastroenterology	Ulcerative Colitis	Adalimumab	Continuation	Adalimumab and Infliximab: Ulcerative Colitis TA 329 ADULT PATIENTS - Continuation Form	12 months	Tick box
Gastroenterology	Ulcerative Colitis	Adalimumab	Initiation	Adalimumab and Infliximab: Ulcerative Colitis TA 329 ADULT PATIENTS - Initiation Form	14 weeks	Tick box
Gastroenterology	Ulcerative Colitis	Adalimumab	Dose escalation	Adalimumab: Ulcerative Colitis TA 329 ADULT PATIENTS - Dose Escalation Notification	12 weeks	Tick box
Gastroenterology	Ulcerative Colitis	Adalimumab	Ongoing dose escalation	Adalimumab: Ulcerative Colitis TA 329 ADULT PATIENTS - Ongoing Dose Escalation Prior Approval Form	12 weeks	Prior approval
Gastroenterology	Ulcerative Colitis	Golimumab	Continuation	Golimumab: Ulcerative Colitis TA 329 ADULT PATIENTS - Continuation Form	12 months	Tick box
Gastroenterology	Ulcerative Colitis	Golimumab	Initiation	Golimumab: Ulcerative Colitis TA 329 ADULT PATIENTS - Initiation Form	14 weeks	Tick box
Gastroenterology	Ulcerative Colitis	Infliximab	Continuation	Adalimumab and Infliximab: Ulcerative Colitis TA 329 ADULT PATIENTS - Continuation Form	12 months	Tick box
Gastroenterology	Ulcerative Colitis	Infliximab	Initiation	Adalimumab and Infliximab: Ulcerative Colitis TA 329 ADULT PATIENTS - Initiation Form	14 weeks	Tick box
Gastroenterology	Ulcerative Colitis	Infliximab	Dose escalation	Infliximab: Ulcerative Colitis TA 329 ADULT PATIENTS - Dose Escalation Notification	24 weeks	Tick box
Gastroenterology	Ulcerative Colitis	Infliximab	Ongoing dose escalation	Infliximab: Ulcerative Colitis TA 329 ADULT PATIENTS - Ongoing Dose Escalation Prior Approval	24 weeks	Prior approval
Gastroenterology	Ulcerative Colitis	Vedolizumab	Continuation	Vedolizumab: Ulcerative Colitis TA 342 ADULT PATIENTS - Continuation Form	12 months	Tick box
Gastroenterology	Ulcerative Colitis	Vedolizumab	Initiation	Vedolizumab: Ulcerative Colitis TA 342 ADULT PATIENTS - Initiation Form	16 weeks	Tick box
Haematology						
Haematology	Chronic Immune (Idiopathic) Thrombocytopena	Eltrombopag	Continuation/Dose Change	Eltrombopag: Treatment of Chronic Immune (Idiopathic) Thrombocytopenia Purpura TA 293 ADULT PATIENTS - Continuation or Dose Change Form	12 months	Tick box
Haematology	Chronic Immune (Idiopathic) Thrombocytopena	Eltrombopag	Initiation	Eltrombopag: Treatment of Chronic Immune (Idiopathic) Thrombocytopenia Purpura TA 293 ADULT PATIENTS - Initiation Form	12 months	Tick box
Haematology	Chronic Immune (Idiopathic) Thrombocytopena	Rituximab	Initiation	Rituximab: Chronic Immune (Idiopathic) Thrombocytopenia Purpura ADULT PATIENTS - Initiation Form	4 doses	Tick box
Haematology	Chronic Immune (Idiopathic) Thrombocytopena	Romiplostim	Continuation	Romiplostim: Chronic Immune (Idiopathic) Thrombocytopenia Purpura TA221 ADULT PATIENTS - Continuation or Dose Change Form	12 months	Tick box
Haematology	Chronic Immune (Idiopathic) Thrombocytopena	Romiplostim	Initiation	Romiplostim: Chronic Immune (Idiopathic) Thrombocytopenia Purpura TA221 ADULT PATIENTS - Initiation Form	12 months	Tick box
Ophthalmology						
Ophthalmology	Wet Age-related Macular Degeneration	Aflibercept	LEFT EYE Continuation	Aflibercept: Wet Age-related Macular Degeneration (AMD) TA 294 ADULT PATIENTS - LEFT EYE Continuation Form	12 months	Tick box
Ophthalmology	Wet Age-related Macular Degeneration	Aflibercept	RIGHT EYE Continuation	Aflibercept: Wet Age-related Macular Degeneration (AMD) TA 294 ADULT PATIENTS - RIGHT EYE Continuation Form	12 months	Tick box
Ophthalmology	Wet Age-related Macular Degeneration	Aflibercept	LEFT EYE Initiation	Aflibercept: Wet Age-related Macular Degeneration (AMD) TA 294 ADULT PATIENTS - LEFT EYE Initiation Form	12 months	Tick box
Ophthalmology	Wet Age-related Macular Degeneration	Aflibercept	RIGHT EYE Initiation	Aflibercept: Wet Age-related Macular Degeneration (AMD) TA 294 ADULT PATIENTS - RIGHT EYE Initiation Form	12 months	Tick box
Ophthalmology	Wet Age-related Macular Degeneration	Ranibizumab	LEFT EYE Continuation	Ranibizumab: Wet Age-related Macular Degeneration (AMD) TA 155 ADULT PATIENTS - LEFT EYE Continuation Form	12 months	Tick box
Ophthalmology	Wet Age-related Macular Degeneration	Ranibizumab	RIGHT EYE Continuation	Ranibizumab: Wet Age-related Macular Degeneration (AMD) TA 155 ADULT PATIENTS - RIGHT EYE Continuation Form	12 months	Tick box
Ophthalmology	Wet Age-related Macular Degeneration	Ranibizumab	LEFT EYE Initiation	Ranibizumab: Wet Age-related Macular Degeneration (AMD) TA 155 ADULT PATIENTS - LEFT EYE Initiation Form	12 months	Tick box
Ophthalmology	Wet Age-related Macular Degeneration	Ranibizumab	RIGHT EYE Initiation	Ranibizumab: Wet Age-related Macular Degeneration (AMD) TA 155 ADULT PATIENTS - RIGHT EYE Initiation Form	12 months	Tick box
Ophthalmology	Branch Retinal Vein Occlusion	Aflibercept	LEFT EYE Continuation	Aflibercept: Branch Retinal Vein Occlusion (BRVO) TA 409 ADULT PATIENTS - LEFT EYE Continuation Form	12 months	Tick box
Ophthalmology	Branch Retinal Vein Occlusion	Aflibercept	RIGHT EYE Continuation	Aflibercept: Branch Retinal Vein Occlusion (BRVO) TA 409 ADULT PATIENTS - RIGHT EYE Continuation Form	12 months	Tick box
Ophthalmology	Branch Retinal Vein Occlusion	Aflibercept	LEFT EYE Initiation	Aflibercept: Branch Retinal Vein Occlusion (BRVO) TA 409 ADULT PATIENTS - LEFT EYE Initiation Form	12 months	Tick box
Ophthalmology	Branch Retinal Vein Occlusion	Aflibercept	RIGHT EYE Initiation	Aflibercept: Branch Retinal Vein Occlusion (BRVO) TA 409 ADULT PATIENTS - RIGHT EYE Initiation Form	12 months	Tick box
Ophthalmology	Branch Retinal Vein Occlusion	Ranibizumab	LEFT EYE Continuation	Ranibizumab: Branch Retinal Vein Occlusion (BRVO) TA 283 ADULT PATIENTS - LEFT EYE Continuation Form	12 months	Tick box
Ophthalmology	Branch Retinal Vein Occlusion	Ranibizumab	RIGHT EYE Continuation	Ranibizumab: Branch Retinal Vein Occlusion (BRVO) TA 283 ADULT PATIENTS - RIGHT EYE Continuation Form	12 months	Tick box
Ophthalmology	Branch Retinal Vein Occlusion	Ranibizumab	LEFT EYE Initiation	Ranibizumab: Branch Retinal Vein Occlusion (BRVO) TA 283 ADULT PATIENTS - LEFT EYE Initiation Form	12 months	Tick box
Ophthalmology	Branch Retinal Vein Occlusion	Ranibizumab	RIGHT EYE Initiation	Ranibizumab: Branch Retinal Vein Occlusion (BRVO) TA 283 ADULT PATIENTS - RIGHT EYE Initiation Form	12 months	Tick box
Ophthalmology	Branch Retinal Vein Occlusion	Dexamethasone Implant	LEFT EYE Initiation	Dexamethasone Implant: Branch Retinal Vein Occlusion (BRVO) TA 229 ADULT PATIENTS - LEFT EYE Initiation Form	6 months	Tick box
Ophthalmology	Branch Retinal Vein Occlusion	Dexamethasone Implant	LEFT EYE Repeat	Dexamethasone Implant: Branch Retinal Vein Occlusion (BRVO) TA 229 ADULT PATIENTS - LEFT EYE Repeat Form	6 months	Tick box
Ophthalmology	Branch Retinal Vein Occlusion	Dexamethasone Implant	RIGHT EYE Initiation	Dexamethasone Implant: Branch Retinal Vein Occlusion (BRVO) TA 229 ADULT PATIENTS - RIGHT EYE Initiation Form	6 months	Tick box
Ophthalmology	Branch Retinal Vein Occlusion	Dexamethasone Implant	RIGHT EYE Repeat	Dexamethasone Implant: Branch Retinal Vein Occlusion (BRVO) TA 229 ADULT PATIENTS - RIGHT EYE Repeat Form	6 months	Tick box
Ophthalmology	Choroidal Neovascularisation	Aflibercept	LEFT EYE Continuation	Aflibercept: Choroidal Neovascularisation (CNV) TA 486 ADULT PATIENTS - LEFT EYE Continuation Form	12 months	Tick box
Ophthalmology	Choroidal Neovascularisation	Aflibercept	RIGHT EYE Continuation	Aflibercept: Choroidal Neovascularisation (CNV) TA 486 ADULT PATIENTS - RIGHT EYE Continuation Form	12 months	Tick box
Ophthalmology	Choroidal Neovascularisation	Aflibercept	LEFT EYE Initiation	Aflibercept: Choroidal Neovascularisation (CNV) TA 486 ADULT PATIENTS - LEFT EYE Initiation Form	12 months	Tick box
Ophthalmology	Choroidal Neovascularisation	Aflibercept	RIGHT EYE Initiation	Aflibercept: Choroidal Neovascularisation (CNV) TA 486 ADULT PATIENTS - RIGHT EYE Initiation Form	12 months	Tick box
Ophthalmology	Choroidal Neovascularisation	Ranibizumab	LEFT EYE Continuation	Ranibizumab: Choroidal Neovascularisation (CNV) TA 298 ADULT PATIENTS - LEFT EYE Continuation Form	12 months	Tick box
Ophthalmology	Choroidal Neovascularisation	Ranibizumab	RIGHT EYE Continuation	Ranibizumab: Choroidal Neovascularisation (CNV) TA 298 ADULT PATIENTS - RIGHT EYE Continuation Form	12 months	Tick box
Ophthalmology	Choroidal Neovascularisation	Ranibizumab	LEFT EYE Initiation	Ranibizumab: Choroidal Neovascularisation (CNV) TA 298 ADULT PATIENTS - LEFT EYE Initiation Form	12 months	Tick box

Ophthalmology	Choroidal Neovascularisation	Ranibizumab	RIGHT EYE Initiation	Ranibizumab: Choroidal Neovascularisation (CNV) TA 298 ADULT PATIENTS - RIGHT EYE Initiation Form	12 months	Tick box
Ophthalmology	Central Retinal Vein Occlusion	Aflibercept	LEFT EYE Continuation	Aflibercept: Central Retinal Vein Occlusion (CRVO) TA 305 ADULT PATIENTS - LEFT EYE Continuation Form	12 months	Tick box
Ophthalmology	Central Retinal Vein Occlusion	Aflibercept	RIGHT EYE Continuation	Aflibercept: Central Retinal Vein Occlusion (CRVO) TA 305 ADULT PATIENTS - RIGHT EYE Continuation Form	12 months	Tick box
Ophthalmology	Central Retinal Vein Occlusion	Aflibercept	LEFT EYE Initiation	Aflibercept: Central Retinal Vein Occlusion (CRVO) TA 305 ADULT PATIENTS - LEFT EYE Initiation Form	12 months	Tick box
Ophthalmology	Central Retinal Vein Occlusion	Aflibercept	RIGHT EYE Initiation	Aflibercept: Central Retinal Vein Occlusion (CRVO) TA 305 ADULT PATIENTS - RIGHT EYE Initiation Form	12 months	Tick box
Ophthalmology	Central Retinal Vein Occlusion	Ranibizumab	LEFT EYE Continuation	Ranibizumab: Central Retinal Vein Occlusion (CRVO) TA 283 ADULT PATIENTS - LEFT EYE Continuation Form	12 months	Tick box
Ophthalmology	Central Retinal Vein Occlusion	Ranibizumab	RIGHT EYE Continuation	Ranibizumab: Central Retinal Vein Occlusion (CRVO) TA 283 ADULT PATIENTS - RIGHT EYE Continuation Form	12 months	Tick box
Ophthalmology	Central Retinal Vein Occlusion	Ranibizumab	LEFT EYE Initiation	Ranibizumab: Central Retinal Vein Occlusion (CRVO) TA 283 ADULT PATIENTS - LEFT EYE Initiation Form	12 months	Tick box
Ophthalmology	Central Retinal Vein Occlusion	Ranibizumab	RIGHT EYE Initiation	Ranibizumab: Central Retinal Vein Occlusion (CRVO) TA 283 ADULT PATIENTS - RIGHT EYE Initiation Form	12 months	Tick box
Ophthalmology	Central Retinal Vein Occlusion	Dexamethasone Implant	LEFT EYE Initiation	Dexamethasone Implant: Central Retinal Vein Occlusion (CRVO) TA 229 ADULT PATIENTS - LEFT EYE Initiation Form	6 months	Tick box
Ophthalmology	Central Retinal Vein Occlusion	Dexamethasone Implant	LEFT EYE Repeat	Dexamethasone Implant: Central Retinal Vein Occlusion (CRVO) TA 229 ADULT PATIENTS - LEFT EYE Repeat Form	6 months	Tick box
Ophthalmology	Central Retinal Vein Occlusion	Dexamethasone Implant	RIGHT EYE Initiation	Dexamethasone Implant: Central Retinal Vein Occlusion (CRVO) TA 229 ADULT PATIENTS - RIGHT EYE Initiation Form	6 months	Tick box
Ophthalmology	Central Retinal Vein Occlusion	Dexamethasone Implant	RIGHT EYE Repeat	Dexamethasone Implant: Central Retinal Vein Occlusion (CRVO) TA 229 ADULT PATIENTS - RIGHT EYE Repeat Form	6 months	Tick box
Ophthalmology	Diabetic Macular Oedema	Aflibercept	LEFT EYE Continuation	Aflibercept: Diabetic Macular Oedema (DMO) TA 346 ADULT PATIENTS - LEFT EYE Continuation Form	12 months	Tick box
Ophthalmology	Diabetic Macular Oedema	Aflibercept	RIGHT EYE Continuation	Aflibercept: Diabetic Macular Oedema (DMO) TA 346 ADULT PATIENTS - RIGHT EYE Continuation Form	12 months	Tick box
Ophthalmology	Diabetic Macular Oedema	Aflibercept	LEFT EYE Initiation	Aflibercept: Diabetic Macular Oedema (DMO) TA 346 ADULT PATIENTS - LEFT EYE Initiation Form	12 months	Tick box
Ophthalmology	Diabetic Macular Oedema	Aflibercept	RIGHT EYE Initiation	Aflibercept: Diabetic Macular Oedema (DMO) TA 346 ADULT PATIENTS - RIGHT EYE Initiation Form	12 months	Tick box
Ophthalmology	Diabetic Macular Oedema	Ranibizumab	LEFT EYE Continuation	Ranibizumab: Diabetic Macular Oedema (DMO) TA 274 ADULT PATIENTS - LEFT EYE Continuation Form	12 months	Tick box
Ophthalmology	Diabetic Macular Oedema	Ranibizumab	RIGHT EYE Continuation	Ranibizumab: Diabetic Macular Oedema (DMO) TA 274 ADULT PATIENTS - RIGHT EYE Continuation Form	12 months	Tick box
Ophthalmology	Diabetic Macular Oedema	Ranibizumab	LEFT EYE Initiation	Ranibizumab: Diabetic Macular Oedema (DMO) TA 274 ADULT PATIENTS - LEFT EYE Initiation Form	12 months	Tick box
Ophthalmology	Diabetic Macular Oedema	Ranibizumab	RIGHT EYE Initiation	Ranibizumab: Diabetic Macular Oedema (DMO) TA 274 ADULT PATIENTS - RIGHT EYE Initiation Form	12 months	Tick box
Ophthalmology	Diabetic Macular Oedema	Dexamethasone Implant	LEFT EYE Initiation	Dexamethasone Implant: Diabetic Macular Oedema (DMO) TA 349 ADULT PATIENTS - LEFT EYE Initiation Form	6 months	Tick box
Ophthalmology	Diabetic Macular Oedema	Dexamethasone Implant	LEFT EYE Repeat	Dexamethasone Implant: Diabetic Macular Oedema (DMO) TA 349 ADULT PATIENTS - LEFT EYE Repeat Form	6 months	Tick box
Ophthalmology	Diabetic Macular Oedema	Dexamethasone Implant	RIGHT EYE Initiation	Dexamethasone Implant: Diabetic Macular Oedema (DMO) TA 349 ADULT PATIENTS - RIGHT EYE Initiation Form	6 months	Tick box
Ophthalmology	Diabetic Macular Oedema	Dexamethasone Implant	RIGHT EYE Repeat	Dexamethasone Implant: Diabetic Macular Oedema (DMO) TA 349 ADULT PATIENTS - RIGHT EYE Repeat Form	6 months	Tick box
Ophthalmology	Diabetic Macular Oedema	Fluocinolone Acetonide	LEFT EYE Initiation	Fluocinolone Acetonide: Diabetic Macular Oedema (DMO) TA 301 ADULT PATIENTS - LEFT EYE Initiation Form	36 months	Tick box
Ophthalmology	Diabetic Macular Oedema	Fluocinolone Acetonide	LEFT EYE Repeat	Fluocinolone Acetonide: Diabetic Macular Oedema (DMO) TA 301 ADULT PATIENTS - LEFT EYE Repeat Form	36 months	Tick box
Ophthalmology	Diabetic Macular Oedema	Fluocinolone Acetonide	RIGHT EYE Initiation	Fluocinolone Acetonide: Diabetic Macular Oedema (DMO) TA 301 ADULT PATIENTS - RIGHT EYE Initiation Form	36 months	Tick box
Ophthalmology	Diabetic Macular Oedema	Fluocinolone Acetonide	RIGHT EYE Repeat	Fluocinolone Acetonide: Diabetic Macular Oedema (DMO) TA 301 ADULT PATIENTS - RIGHT EYE Repeat Form	36 months	Tick box
Ophthalmology	Vitreomacular Traction	Ocriplasmin	LEFT EYE Single dose	Ocriplasmin: Vitreomacular Traction TA 297 ADULT PATIENTS - LEFT EYE Single Dose Form	1 dose	Tick box
Ophthalmology	Vitreomacular Traction	Ocriplasmin	RIGHT EYE Single dose	Ocriplasmin: Vitreomacular Traction TA 297 ADULT PATIENTS - RIGHT EYE Single Dose Form	1 dose	Tick box
Ophthalmology	Rubeotic/Neovascular Glaucoma	Bevacizumab	LEFT EYE Single dose	Bevacizumab: Rubeotic/Neovascular Glaucoma - UNLICENSED- ADULT PATIENTS - LEFT EYE SINGLE DOSE Form	1 dose	Tick box
Ophthalmology	Rubeotic/Neovascular Glaucoma	Bevacizumab	RIGHT EYE Single dose	Bevacizumab: Rubeotic/Neovascular Glaucoma - UNLICENSED- ADULT PATIENTS - RIGHT EYE SINGLE DOSE Form	1 dose	Tick box
Ophthalmology	Uncontrolled Proliferative Diabetic Retinopathy	Bevacizumab	LEFT EYE Single dose	Bevacizumab: Uncontrolled Proliferative Diabetic Retinopathy - UNLICENSED- ADULT PATIENTS - LEFT EYE SINGLE DOSE Form	1 dose	Tick box
Ophthalmology	Uncontrolled Proliferative Diabetic Retinopathy	Bevacizumab	RIGHT EYE Single dose	Bevacizumab: Uncontrolled Proliferative Diabetic Retinopathy - UNLICENSED- ADULT PATIENTS - RIGHT EYE SINGLE DOSE Form	1 dose	Tick box
Ophthalmology	Wet Age-related Macular Degeneration	Bevacizumab	LEFT EYE 3 doses	Bevacizumab: Wet Age-related Macular Degeneration (AMD) Under NICE Threshold - UNLICENSED- ADULT PATIENTS - LEFT EYE 3 Dose Course	3 doses	Tick box
Ophthalmology	Wet Age-related Macular Degeneration	Bevacizumab	RIGHT EYE 3 doses	Bevacizumab: Wet Age-related Macular Degeneration (AMD) Under NICE Threshold - UNLICENSED- ADULT PATIENTS - RIGHT EYE 3 Dose Course	3 doses	Tick box